How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Medical Varicose Vein Socks Market
- By Compression Level: Mild Compression (8-15 mmHg), Moderate Compression (15-20 mmHg), Firm Compression (20-30 mmHg), Extra Firm Compression (30-40 mmHg)
- By Product Type: Knee-High Socks, Thigh-High Stockings, Pantyhose/Full-Length Stockings, Open Toe Socks
- By Material: Nylon, Spandex, Cotton Blends, Microfiber, Latex-Free Materials
- By End User: Hospitals and Clinics, Home Care Settings, Specialty Medical Stores, Online Retail
- By Distribution Channel: Pharmacies and Drugstores, E-commerce Platforms, Medical Supply Distributors, Direct Sales
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Mild Compression (8-15 mmHg) leads By Compression Level at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 296 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.178 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.186 →
Full report · locked preview
Everything inside the Medical Varicose Vein Socks Market report
A complete, evidence-based study - 12 chapters and 124 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Compression Level 4
Product Type 4
Material 5
End User 4
Distribution Channel 4
Companies profiled
Medi GmbH
Sigvaris Group
Juzo
BSN Medical (Essity)
Jobst (BSN Medical)
Therafirm
CEP (Hahn GmbH & Co. KG)
Futuro (3M)
Venosan
Activa Healthcare
L&R (Lohmann & Rauscher)
Ortho Europe
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Medi GmbH
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Sigvaris Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Juzo
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →BSN Medical (Essity)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Jobst (BSN Medical)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Therafirm
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →CEP (Hahn GmbH & Co. KG)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Futuro (3M)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Venosan
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Activa Healthcare
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →L&R (Lohmann & Rauscher)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Ortho Europe
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →RelaxSan
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Sanyleg
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Zensah
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,866M by 2033 · 5.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Mild Compression (8-15 mmHg)58.8
- Moderate Compression (15-20 mmHg)16.3
- Firm Compression (20-30 mmHg)15.3
- Extra Firm Compression (30-40 mmHg)9.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$621.4M → $881.7M · 4.5%
Europe$433.1M → $638.5M · 5.0%
Asia Pacific$395.5M → $583.2M · 5.0%
Latin America$244.8M → $347.1M · 4.5%
Middle East and Africa$188.3M → $268.7M · 4.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.342026
5.352027
5.362028
5.382029
5.392030
5.402031
5.412032
5.422033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Medi GmbH20.1
- Sigvaris Group18.8
- Juzo3.2
- BSN Medical (Essity)10.6
- Jobst (BSN Medical)10.2
- Therafirm9.0
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Compression Level16.4%
Product Type11.7%
Material27.6%
End User28.1%
Distribution Channel16.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.4
- Europe23.5
- Asia Pacific21.4
- Latin America12.8
- Middle East and Africa9.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Medi GmbH | 79 | 78 | 97 | 80 | 94 | 95 | 87 |
| Sigvaris Group | 78 | 74 | 84 | 75 | 89 | 68 | 78 |
| Juzo | 68 | 75 | 74 | 65 | 76 | 80 | 73 |
| BSN Medical (Essity) | 76 | 74 | 70 | 62 | 58 | 71 | 69 |
| Jobst (BSN Medical) | 67 | 64 | 55 | 71 | 61 | 75 | 66 |
| Therafirm | 68 | 68 | 68 | 49 | 58 | 57 | 61 |
| CEP (Hahn GmbH & Co. KG) | 42 | 59 | 58 | 43 | 63 | 59 | 54 |
| Futuro (3M) | 57 | 37 | 59 | 60 | 47 | 54 | 52 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Medi GmbH
- Sigvaris Group
- Juzo
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Medi GmbH | ✓ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Sigvaris Group | ◐ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Juzo | ◐ | ◐ | ◐ | − | ✓ | ◐ |
| BSN Medical (Essity) | ✓ | ✓ | ◐ | ◐ | − | ✓ |
| Jobst (BSN Medical) | ✓ | − | − | ◐ | ◐ | ◐ |
| Therafirm | ◐ | ◐ | ◐ | − | − | ◐ |
| CEP (Hahn GmbH & Co. KG) | − | − | ◐ | − | − | − |
| Futuro (3M) | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Medi GmbH87
2Sigvaris Group78
3Juzo73
4BSN Medical (Essity)69
5Jobst (BSN Medical)66
6Therafirm61
7CEP (Hahn GmbH & Co. KG)54
8Futuro (3M)52
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Medi GmbHSigvaris Group
Challenger2
Strong scale, closing on the leaders.
JuzoBSN Medical (Essity)
Contender2
Focused players with pockets of strength.
Jobst (BSN Medical)Therafirm
Niche2
Specialists in a single segment or region.
CEP (Hahn GmbH & Co. KG)Futuro (3M)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Compression Level in North America, then scale across Medical Varicose Vein Socks Market — a $46M beachhead inside a $678M market.
Beachhead (SOM)$46Mobtainable near-term
Serviceable (SAM)$258Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Mild Compression (8-15 mmHg)
Best fit — highest urgency & budget in Compression Level.
Economic buyer79 fit
Moderate Compression (15-20 mmHg)
Strong fit — clear ROI and a fast path to value.
End user66 fit
Firm Compression (20-30 mmHg)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Compression Level in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Product Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Material
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel31%
Digital / self-serve18%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Compression Level leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Medical Varicose Vein Socks Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified20%
Evaluation12%
Closed-won7%
$21.1KCAC
$84KLTV
4.0:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Medical Varicose Vein Socks Market is a durable-growth opportunity — $6.64B by 2033, compounding at 7.6%.
TAM · 2025$3.70Btoday
TAM · 2033$6.64Bforecast
CAGR7.6%2027–2033
Cumulative$45.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.64BTotal addressable market
SAM$2.41BServiceable available market
SOM$417MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.6% CAGR
Demand compounds through 2033, outpacing GDP across Compression Level.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Compression Level moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.64BLarge & growingTAM by 2033 at 7.6% CAGR
$2.41BServiceable nowreachable with today’s model
$417MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.18BBear4.9% CAGR
$6.64BBase7.6% CAGR
$8.51BBull10.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Product Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Medical Varicose Vein Socks Market — a $12.5B market by 2033. Plan: grow share from 9.5% to 16.2%.
Market size · 2033$12.5Btotal addressable
Market CAGR11.0%2027–2033
Target share16.2%from 9.5% today
Revenue ambition$2.02Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.5% | 16.2% | At risk |
| Revenue | $1.10B | $2.02B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 28.9% | 43.9% | Behind |
| Customer retention | 86.0% | 94.3% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Compression Level
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Product Type capability
A defensible second engine — invest in Product Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Compression Level share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Product Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $248M capacity & capability investment
- Greenlight bolt-on M&A in Product Type
- Authorise North America expansion plan
- Fund R&D program for Compression Level leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Medical Varicose Vein Socks Market conversation — a $779M market you can size, segment and defend in minutes.
Market size · 2033$779Mtotal opportunity
Growth6.4%CAGR to 2033
Addressable buyers1,550+accounts in scope
Typical ROI4.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Compression Level
Goal Grow share in Compression Level
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.5×return on cost, year one
< 2 mopayback period
$52K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Medi GmbHSigvaris GroupJuzoBSN Medical (Essity)Jobst (BSN Medical)TherafirmCEP (Hahn GmbH & Co. KG)Futuro (3M)+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Medical Varicose Vein Socks Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Medical Varicose Vein Socks Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Medical Variable Force Spring Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportMedical Valves Market
Market size, share, segmentation and regional forecast.
$826M market · 2025 base year
View reportMedical Vacuum Therapy Apparatus Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportMedical Vacuum Station Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportMedical Vacuum Splints Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportMedical Vacuum Pump Systems Market
Market size, share, segmentation and regional forecast.
$632M market · 2025 base year
View reportMedical Vacuum Plant Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportMedical Vacuum Ovens Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportMedical Vacuum Negative Press Machine Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportMedical Vacuum Filters Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportMedical Vacuum Drying Cabinet Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportMedical Vacuum Cupping Suction Therapy Device Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.